Airway cellular response to two different immunosuppressive regimens in lung transplant recipients

Clinical Transplantation

Volumn 19, Issue 2, 2005, Pages 243-249

  Slebos, Dirk Jan ^a   Kauffman, Henk F ^a   Koöeter, Gerard H ^a   Verschuuren, Erik A M ^a   van der Bij, Wim ^a   Postma, Dirkje S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bronchoalveolar lavage; CD4 CD8 ratio; Immunosuppression; Lung transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CD4 ANTIGEN; CD8 ANTIGEN; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOIMMUNITY; ARTICLE; BRONCHIOLITIS OBLITERANS; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RESPIRATORY TRACT DISEASE; STATISTICAL ANALYSIS; SUPPRESSOR CELL; SURVIVAL RATE;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; BRONCHOALVEOLAR LAVAGE FLUID; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL PROTOCOLS; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; LYMPHOCYTES; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 15844406548     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00330.x     Document Type: Article

References (26)

1. van den Berg JW, Postma DS, Koëter GH, van der Bij W. New immunosuppressive drugs and lung transplantation: last or least? Thorax 1999: 54: 550.
2. Brock MV, Borja MC, Ferber L et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001: 20: 1282.
3. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999: 57: 207.
4. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003: 35(Suppl.): 7S.
5. Treede H, Klepetko W, Reichenspurner H et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001: 20: 511.
6. Garrity ER Jr, Villanueva J, Bhorade SM, Husain AN, Vigneswaran WT. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001: 71: 773.
7. Revell MP, Lewis ME, Llwellyn-Jones CG, Wilson IC, Bonser RS. Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant 2000: 19: 1219.
8. Slebos DJ, Scholma J, Boezen HM et al. Longitudinal profile of bronchoalveolar lavage cell characteristics in patients with a good outcome after lung transplantation. Am J Respir Crit Care Med 2002: 165: 501.
9. Slebos DJ, Postma DS, Koëter GH, van der Bij W, Boezen M, Kauffman HF. Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. J Heart Lung Transplant 2004: 23: 532.
10. Yousem SA, Berry GJ, Cagle PT et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996: 15: 1.
11. Van der Giessen M, Van den Berg AP, Van der Bij W, Postma DS, van Son WJ, The TH. Quantitative measurement of CMV-specific IgG- and IgM-antibodies in relation to CMV antigenemia and disease activity in kidney recipients with an active CMV infection. Clin Exp Immunol 1990: 80: 56.
12. Cooper JD, Billingham ME, Egan T et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993: 12: 713.
13. Ouwens JP, van der Mark TW, Koëter GH, de Boer WJ, Grevink RG, van der Bij W. Bronchiolar airflow impairment after lung transplantation: an early and common manifestation. J Heart Lung Transplant 2002: 21: 1056.
14. Scholma J, Slebos DJ, Boezen HM et al. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2000: 162: 2221.
15. Chan CC, Abi-Saleh WJ, Arroliga AC et al. Diagnostic yield and therapeutic impact of flexible bronchoscopy in lung transplant recipients. J Heart Lung Transplant 1996: 15: 196.
16. Kelly CA, Kotre CJ, Ward C, Hendrick DJ, Walthers EH. Anatomical distribution of bronchoalveolar lavage fluid as assessed by digital subtraction radiography. Thorax 1987: 42: 624.
17. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992: 357: 695.
18. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992: 89: 3686.
19. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993: 14: 264.
20. Malinowski K, Ye H, Waltzer WC. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes. Transplant Proc 2000: 32: 773.
21. Jiang H, Yang X, Soriano RN, Fujimura T, Krishnan K, Kobayashi M. Distinct patterns of cytokine gene suppression by the equivalent effective doses of cyclosporine and tacrolimus in rat heart allografts. Immunobiology 2000: 202: 280.
22. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999: 116: 127.
23. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999: 67: 276.
24. Boelaars-van Haperen MJ, Baan CC, van Riemsdijk IC, Ijzermans JN, Weimar W. Treatment with the chimeric anti-IL-2Ralpha basiliximab affects both the IL-2 and IL-15 signalling pathways after clinical kidney transplantation. Transplant Proc 2001: 33: 1007.
25. Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25 + CD4 + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001: 182: 18.
26. Meloni F, Vitulo P, Bianco AM et al. Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 2004: 77: 762.